GSKH - ETF AI Analysis
Top Page
GSK plc ADRhedged (GSKH)
Rating:76Outperform
Price Target:―
Positive Factors
Focused Healthcare Exposure
The ETF is heavily invested in the healthcare sector, giving investors targeted exposure to a defensive industry that can be more resilient in economic slowdowns.
Low Expense Ratio
The fund charges a relatively low fee, which helps investors keep more of any returns over time.
Recent Short-Term Recovery
Despite weak year-to-date results, the ETF has shown a strong rebound over the last three months, suggesting some recent improvement in performance.
Negative Factors
Extreme Single-Stock Concentration
Almost the entire fund is invested in one company, GlaxoSmithKline, which greatly increases the risk if that stock performs poorly.
Recent Weak Overall Performance
The ETF has delivered negative returns so far this year and over the past month, indicating recent performance has been weak.
Very Limited Diversification
With nearly all assets in one sector and one stock, the fund offers little protection against company-specific or sector-specific setbacks.
GSKH vs. SPDR S&P 500 ETF (SPY)
AUM738.76K
RegionEurope
Expense Ratio0.19%
Beta0.32
IssuerADRhedged
Inception DateJan 07, 2025
Dividend Yield1.57%
Asset ClassEquity
Index TrackedGSK plc - Benchmark Price Return
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume268
30 Day Avg. Volume334
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
79.18Price Target Upside― Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GSKH Summary
GSKH is an ETF that tracks the GSK plc Benchmark Price Return index, giving you focused exposure to the pharmaceutical side of the healthcare sector. It mainly holds shares of GSK (GlaxoSmithKline), a large global drug company known for vaccines and medicines. Investors might consider GSKH if they want simple, one-stock-style exposure to a major pharma company, with some currency fluctuations hedged out, and potential long-term growth from new drug discoveries and an aging population. A key risk is that it’s highly concentrated in one company, so its price can swing sharply with GSK’s fortunes.
How much will it cost me?The GSK plc ADRhedged ETF has an expense ratio of 0.19%, which means you’ll pay $1.90 per year for every $1,000 invested. This is lower than average for actively managed ETFs, as it focuses on a specific niche in the pharmaceutical sector while offering currency hedging benefits.
What would affect this ETF?The GSKH ETF could benefit from positive trends in the pharmaceutical sector, such as advancements in drug development, regulatory approvals, and increased demand driven by aging populations and global health initiatives. However, it may face challenges from stricter regulations, patent expirations, or economic downturns that could impact healthcare spending. Additionally, its focus on the U.K. market and reliance on GlaxoSmithKline may expose it to risks tied to regional economic conditions or company-specific performance.
GSKH Top 10 Holdings
GSKH is essentially a one-stock story, with GlaxoSmithKline doing almost all the heavy lifting. The fund is laser-focused on European healthcare, and more specifically the U.K. pharmaceutical scene, so investors are really betting on GSK’s pipeline and pricing power. With the stock rising steadily in recent months and sentiment improving on the back of stronger specialty medicine sales, GSK is currently pulling the ETF higher rather than holding it back. That makes GSKH a concentrated, high-conviction play rather than a broad healthcare basket.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| GlaxoSmithKline | 96.49% | $705.91K | $104.09B | 32.11% | 77 Outperform |
GSKH Technical Analysis
Neutral
―
Price Trends
75.67
Negative
71.44
Positive
63.34
Positive
Market Momentum
-0.95
Positive
32.75
Neutral
2.40
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GSKH, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 78.17, equal to the 50-day MA of 75.67, and equal to the 200-day MA of 63.34, indicating a neutral trend. The MACD of -0.95 indicates Positive momentum. The RSI at 32.75 is Neutral, neither overbought nor oversold. The STOCH value of 2.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GSKH.
GSKH Peer Comparison
Comparison Results
Performance Comparison
GSKH
GSK plc ADRhedged
73.23
18.69
34.27%
SHEH
Shell plc ADRhedged
―
―
―
HSBH
HSBC Holdings plc ADRhedged
―
―
―
NVOH
Novo Nordisk A/S (B Shares) ADRhedged
―
―
―
BPH
BP p.l.c. ADRhedged
―
―
―
ARMH
Arm Holdings PLC ADRhedged
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents